Gene therapy with CX3CL1/Fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma.
about
Regulation of Natural Killer Cell Function by STAT3A meta-analysis for C-X-C chemokine receptor type 4 as a prognostic marker and potential drug target in hepatocellular carcinomaTumor Therapy Applying Membrane-bound Form of Cytokines.Cancer-related transcriptional targets of the circadian gene NPAS2 identified by genome-wide ChIP-on-chip analysis.Differential Expression of CX3CL1 in Hepatitis B Virus-Replicating Hepatoma Cells Can Affect the Migration Activity of CX3CR1+ Immune CellsCX3CL1 promotes breast cancer via transactivation of the EGF pathwayUpregulation of fractalkine contributes to the proliferative response of prostate cancer cells to hypoxia via promoting the G1/S phase transition.CXCL3 contributes to CD133(+) CSCs maintenance and forms a positive feedback regulation loop with CD133 in HCC via Erk1/2 phosphorylation.Intratracheal delivery of CX3CL1-expressing mesenchymal stem cells to multiple lung tumors.CX3CL1/fractalkine shedding by human hepatic stellate cells: contribution to chronic inflammation in the liverFractalkine/CX3CR1: why a single chemokine-receptor duo bears a major and unique therapeutic potential.Role of fractalkine/CX3CL1 and its receptor in the pathogenesis of inflammatory and malignant diseases with emphasis on B cell malignancies.Chemokines and hepatocellular carcinoma.Chemokines in cancer development and progression and their potential as targeting molecules for cancer treatment.Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis.Regulation of cytotoxic T-Lymphocyte trafficking to tumors by chemoattractants: implications for immunotherapy.Membrane-bound form of monocyte chemoattractant protein-1 enhances antitumor effects of suicide gene therapy in a model of hepatocellular carcinoma.CX3CL1 at the crossroad of EGF signals: Relevance for the progression of ERBB2(+) breast carcinoma.Soluble MHC-peptide complexes: tools for the monitoring of T cell responses in clinical trials and basic research.CX3CL1 expression is associated with poor outcome in breast cancer patients.Emerging Roles of G Protein-Coupled Receptors in Hepatocellular Carcinoma.TRAIL/NF-κB/CX3CL1 Mediated Onco-Immuno Crosstalk Leading to TRAIL Resistance of Pancreatic Cancer Cell Lines.
P2860
Q26752551-B6B43806-F818-4077-8CF0-0807469CBCC0Q26800288-98CEFE72-9BFF-4E29-BDD5-C59E99C3C6E0Q33631960-FA9CCE13-DE73-4D08-812C-230D29F87494Q35238035-BEA07574-A0EA-422F-B253-59540C6DDBD2Q35758694-453EDA56-DD6B-4159-82B4-063A72E63D77Q35945009-4DAF065D-3D59-4FAB-AA3D-1E92A3F0CDD0Q36592493-34DBD299-1029-4AA3-8B7C-F0D528FE724EQ36964853-32C8EF36-D55D-4357-A80C-2C2455FA3F19Q37260900-49F95A85-5A93-46E0-BB62-A4A61A97CB5CQ37310641-BDF3214E-E057-4BAC-B63D-B24CE4A1221EQ37670253-21142661-9FF5-481B-803D-89E5529047CBQ37700771-E6348CD6-86B1-4D89-9B7C-C4E1E4C6DA81Q37732087-AF574896-2C01-494A-97E7-B43B65BB9A12Q38223355-AA6BFE16-D220-408C-862F-34C1B37CB538Q38235254-D47473FA-4CAA-4E90-9839-8FFEAD862F5DQ38284345-89EBA470-7AC2-41AB-A4AC-78B77A5174BEQ39382979-11A6CCBD-D6FC-4CC3-84B4-DC4AA99C146AQ41962641-B5A8D376-69EA-4073-B0BD-CDDBCA367104Q42017582-F0291A2E-8468-491A-B2EB-00615137DA7CQ43501063-C5323436-E43F-4971-A702-2FAD0D1216CDQ55127228-87EEBCBE-8959-45D7-872D-A1C95434EC07Q55714794-1926BC42-D2C1-46D4-8611-7841B445E545
P2860
Gene therapy with CX3CL1/Fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Gene therapy with CX3CL1/Fract ...... ouse hepatocellular carcinoma.
@en
type
label
Gene therapy with CX3CL1/Fract ...... ouse hepatocellular carcinoma.
@en
prefLabel
Gene therapy with CX3CL1/Fract ...... ouse hepatocellular carcinoma.
@en
P2093
P356
P1433
P1476
Gene therapy with CX3CL1/Fract ...... ouse hepatocellular carcinoma.
@en
P2093
P2888
P304
P356
10.1038/SJ.GT.3302959
P577
2007-06-28T00:00:00Z
P5875
P6179
1013674814